Palvella Therapeutics (PVLA) Competitors $46.10 +1.46 (+3.27%) As of 08/14/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock PVLA vs. TWST, SRPT, IMCR, BHVN, AUPH, JANX, DYN, TVTX, EWTX, and SDGRShould you be buying Palvella Therapeutics stock or one of its competitors? The main competitors of Palvella Therapeutics include Twist Bioscience (TWST), Sarepta Therapeutics (SRPT), Immunocore (IMCR), Biohaven (BHVN), Aurinia Pharmaceuticals (AUPH), Janux Therapeutics (JANX), Dyne Therapeutics (DYN), Travere Therapeutics (TVTX), Edgewise Therapeutics (EWTX), and Schrodinger (SDGR). These companies are all part of the "pharmaceutical products" industry. Palvella Therapeutics vs. Its Competitors Twist Bioscience Sarepta Therapeutics Immunocore Biohaven Aurinia Pharmaceuticals Janux Therapeutics Dyne Therapeutics Travere Therapeutics Edgewise Therapeutics Schrodinger Twist Bioscience (NASDAQ:TWST) and Palvella Therapeutics (NASDAQ:PVLA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation. Which has better earnings and valuation, TWST or PVLA? Palvella Therapeutics has lower revenue, but higher earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Palvella Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTwist Bioscience$312.97M5.56-$208.73M-$1.45-19.89Palvella Therapeutics$42.81M11.91-$17.43M-$12.10-3.81 Is TWST or PVLA more profitable? Palvella Therapeutics has a net margin of 0.00% compared to Twist Bioscience's net margin of -23.51%. Twist Bioscience's return on equity of -29.03% beat Palvella Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Twist Bioscience-23.51% -29.03% -21.77% Palvella Therapeutics N/A -60.29%-43.30% Which has more volatility and risk, TWST or PVLA? Twist Bioscience has a beta of 2.36, indicating that its stock price is 136% more volatile than the S&P 500. Comparatively, Palvella Therapeutics has a beta of -0.01, indicating that its stock price is 101% less volatile than the S&P 500. Does the media favor TWST or PVLA? In the previous week, Twist Bioscience and Twist Bioscience both had 7 articles in the media. Twist Bioscience's average media sentiment score of 0.75 beat Palvella Therapeutics' score of 0.27 indicating that Twist Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palvella Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend TWST or PVLA? Twist Bioscience currently has a consensus target price of $49.40, suggesting a potential upside of 71.29%. Palvella Therapeutics has a consensus target price of $52.40, suggesting a potential upside of 13.67%. Given Twist Bioscience's higher possible upside, research analysts clearly believe Twist Bioscience is more favorable than Palvella Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Twist Bioscience 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.73Palvella Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 Do insiders and institutionals have more ownership in TWST or PVLA? 40.1% of Palvella Therapeutics shares are held by institutional investors. 3.0% of Twist Bioscience shares are held by insiders. Comparatively, 20.5% of Palvella Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryPalvella Therapeutics beats Twist Bioscience on 9 of the 16 factors compared between the two stocks. Get Palvella Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PVLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PVLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PVLA vs. The Competition Export to ExcelMetricPalvella TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$493.52M$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-3.8120.4930.2825.74Price / Sales11.91356.37460.47115.79Price / CashN/A43.0338.2159.48Price / Book8.268.608.856.15Net Income-$17.43M-$54.65M$3.25B$265.06M7 Day Performance12.71%5.86%3.72%2.60%1 Month Performance66.43%8.86%5.86%2.83%1 Year PerformanceN/A13.33%30.34%25.58% Palvella Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PVLAPalvella Therapeutics1.7439 of 5 stars$46.10+3.3%$52.40+13.7%N/A$493.52M$42.81M-3.81N/ANews CoverageTWSTTwist Bioscience4.0257 of 5 stars$25.90-5.9%$49.40+90.7%-32.3%$1.65B$312.97M-17.86990High Trading VolumeSRPTSarepta Therapeutics4.6129 of 5 stars$16.26-2.9%$49.12+202.1%-84.7%$1.65B$1.90B-6.041,372Trending NewsShort Interest ↑IMCRImmunocore1.9314 of 5 stars$32.10-1.2%$58.89+83.5%-10.6%$1.63B$310.20M-74.65320News CoverageAnalyst RevisionHigh Trading VolumeBHVNBiohaven3.5669 of 5 stars$15.08-1.0%$58.46+287.6%-62.7%$1.56BN/A-1.61239Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionGap DownAUPHAurinia Pharmaceuticals2.8409 of 5 stars$11.61-0.8%$12.00+3.4%+116.3%$1.54B$235.13M27.00300Positive NewsJANXJanux Therapeutics2.3955 of 5 stars$24.18-5.2%$91.89+280.0%-37.8%$1.51B$10.59M-17.7830News CoverageAnalyst RevisionDYNDyne Therapeutics3.3571 of 5 stars$11.59+10.7%$34.94+201.4%-71.5%$1.49BN/A-3.00100High Trading VolumeTVTXTravere Therapeutics2.7228 of 5 stars$17.24+3.4%$32.14+86.4%+113.7%$1.48B$233.18M-6.14460EWTXEdgewise Therapeutics2.2737 of 5 stars$13.52-1.6%$40.55+199.9%-18.3%$1.45BN/A-8.7260News CoverageInsider TradeSDGRSchrodinger3.2614 of 5 stars$19.34-1.5%$32.75+69.3%+2.4%$1.44B$207.54M-7.35790News CoverageAnalyst ForecastGap Down Related Companies and Tools Related Companies TWST Competitors SRPT Competitors IMCR Competitors BHVN Competitors AUPH Competitors JANX Competitors DYN Competitors TVTX Competitors EWTX Competitors SDGR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PVLA) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palvella Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palvella Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access